This article was originally published in The Gray Sheet
Magnetic resonance imaging agent shipments are expected to begin in the first quarter of 2000 following FDA approval via new drug application on Dec. 8. The contrast agent is approved for increased enhancement and visualization of lesions of the brain, spine and liver, including tumors
You may also be interested in...
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.